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ABSTRACT 
Juvenile systemic lupus erythematosus (jSLE) is rare before 5 years-of-age. Monogenic causes 
are suspected in cases of very early onset jSLE particularly in the context of a family history 
and/or consanguinity. We performed whole-exome sequencing and homozygosity mapping in 
the siblings presented with early-onset jSLE. A novel homozygous missense mutation in Protein 
Kinase C Delta (c.1294G>T; p.Gly432Trp) was identified in both patients. One patient showed 
a marked clinical response and resolution inflammation with rituximab therapy. This report 
demonstrates the clinical importance of identifying monogenic causes of rare disease to provide 
a definitive diagnosis, help rationalize treatment, and to facilitate genetic counseling. 
INTRODUCTION 
Systemic lupus erythematosus (SLE) is a complex, severe, chronic, and sometimes life-
threatening disease. Many factors contribute to the development of juvenile SLE (jSLE) 
including genetics, immune dysfunction and environmental factors1. jSLE is rare before 5 
years-of-age, and where this occurs monogenic causes should be considered, particularly if 
there is a family history of SLE, and/or consanguinity. There is now an ever-expanding list of 
monogenic causes of SLE (Table 1), and many present very early in life2-6. We describe two 
siblings who presented with early-onset jSLE in whom we identified a homozygous missense 
mutation in the Protein Kinase C Delta (PRKCD) gene. This report demonstrates the clinical 
importance of identifying monogenic causes of rare disease to provide a rapid and definitive 
diagnosis, help rationalize treatment, and to facilitate genetic counseling.   
 
CASE 
The index case presented at the age of 12-months with scarring alopecia, rash affecting the 
scalp, and a photosensitive malar rash (figure 1A). She also had hepatosplenomegaly and 
bruising of the skin (Figure 1B) and erythematous, non-pruritic, vasculitic rash affecting the 
hands and feet (Figure 1C and D). Oral mucosa was normal. Other features were mild 
monoarthritis of the knee for more than 2 months (clinically not typical of septic arthritis, and 
hence joint not aspirated), and an episode of acute onset of fever, epistaxis, rectal bleeding and 
pancytopenia (haemoglobin 10 g/L, white blood cells 3,060 cells/mL, neutrophil count 1,540 
cells/mL, lymphocyte count 1,010 cells/mL, platelet count 87,200 cells/mL) at the age of 3 
years. Further investigations showed elevated inflammatory markers (elevated ESR 125 
mm/hour and CRP 30 mg/L), positive anti-nuclear antibody 1:320, anti-double stranded DNA 
at 37 (normal < 10) and positive anti-extractable nuclear antigens (ribonucleoprotein, Smith 
and ribosomal P protein). Complement assays were normal: C1q 42 mg/L (normal range 50-
250 mg/L), C3 0.66 g/L (normal range 0.75-1.65 g/L), C4 0.1 g/L (normal range 0.14-0.54 
g/L), functional classical complement pathway assay activity was 75% (normal > 40%), and 
functional alternative complement pathway assay activity was 99% (normal > 10%). Renal 
function and transaminase levels were entirely normal. 
 
The pedigree of the family is shown in figure 2A. She was the second child of consanguineous 
parents (first cousins once removed, i.e. the father was the child of the mother’s first cousin) 
originally from Pakistan. The 5-year-old sister of the index case had identical symptoms and 
signs, which started at the age of 12-months. Her parents were initially healthy, although the 
mother subsequently developed SLE during her third pregnancy. This manifested as mild 
cutaneous malar rash, and arthralgia; but no evidence of pancytopenia or other organ 
involvement. 
 
Both siblings were diagnosed with familial SLE, with fulfillment of 6 out of 11 of the American 
College of Rheumatology classification criteria: malar rash, photosensitivity, arthritis, 
haematological disorder, immunologic disorder and positive ANA7. Both patients were initially 
treated in the first instance with: pulse methylprednisolone (30 mg/kg for 3 days followed by 
oral prednisolone 2 mg/kg/day), hydroxychloroquine (5 mg/kg/day) and azathioprine (2 
mg/kg/day). Despite this, over the next 6 months both children progressively deteriorated with 
pancytopenia with a platelet count in the range of 60,000 – 84,000 cells/mL. Both siblings 
demonstrated only a transient response to further pulses of intravenous methylprednisolone and 
intravenous immunoglobulin (IVIG; 2g/kg, for persistent thrombocytopenia). Therefore, 
rituximab (750 mg/m2, repeated two weeks later) was given to the index case, which resulted 
in a rapid and sustained (13 months at the time of writing) clinical improvement, with complete 
normalisation of the full blood count, and normalisation of inflammatory markers. Rituximab 
(at the same dose) was then given to the older sibling, who unfortunately developed 
anaphylaxis during the second infusion, although still B-cell depleted successfully, and remains 
in clinical remission 12 months later.  
 
Work up for suspected monogenic SLE 
All experimental work was performed with ethical approval (ethics number: 08H071382) and 
with written informed consent from all participants. Both patients were screened using 
conventional Sanger sequencing for known monogenic causes of SLE for: TREX1, SAMHD1, 
C1qA, C1qB, and C1qC, all of which were negative (wild-type). Homozygosity mapping was 
therefore performed in both patients and both parents (see Supplementary Methods). Whole-
exome sequencing (WES) was subsequently performed only in the index case (see 
Supplementary Methods). These studies revealed a homozygous missense mutation 
(c.1294G>T; p.Gly432Trp) in the PRKCD in the index case (see Supplementary Results for 
further details), subsequently confirmed using Sanger sequencing. The c.1294G>T substitution 
is a novel mutation not yet annotated in the dbSNP, the ClinSeq database8, 6500ESP9 or the 
1000 genomes project databases10. This homozygous c.1294G>T mutation was also confirmed 
in her affected sister using Sanger sequencing (figure 2B). Her currently asymptomatic 1-year-
old brother was also homozygous for the same mutation. As expected, both parents were 
confirmed to be heterozygous carriers of the same mutation.  
 
DISCUSSION 
PRKCD is located on chromosome 3p21.31. It encodes protein kinase C delta (PKCδ), a 
member of serine/threonine kinase family that plays a role in apoptosis and proliferation of 
cells11. PKCδ is also known to play a role in B-cell negative selection 12 and has been shown 
to prevent proliferation of B and T cells in response to stimulation in the mouse model13. PKCδ 
deficient mice were found to have features of SLE including anti-double strand DNA 
autoantibodies, glomerulonephritis with IgG containing immune-complex.deposition and 
lymphocyte infiltration in multiple organs13, 14. 
 
The p.Gly432Trp mutation affects the protein kinase activity domain which is located between 
amino acid 349 and 60315. Thus, this mutation is likely to cause a loss of function of the kinase 
activity of PKCδ. The p.Gly432Trp mutation is predicted to be deleterious in pathogenicity 
prediction algorithms (supplemental Table S-3). One limitation of our study was that we did 
not perform any functional experiments to assess protein expression or function, or detailed B 
cell immunotyping (for various practical reasons, including limited access to clinical samples). 
We suggest however, that the clinical features are explained by the mutations we identified in 
PRKCD, particularly since WES did not identify any other plausible genetic cause.  
 
Mutation of PRKCD (p.Gly510Ser) has previously been identified as the cause of early-onset 
jSLE by Belot et al in 3 children of consanguineous unions. Mutations identified were shown 
to cause reduction of PKCδ expression and phosphorylation activity, and transfected 
lymphoblastoid cell lines were found to be resistant to apoptosis, reversible by co-expression 
of non-mutant protein. In the Belot study, primary B-cells from patients and heterozygous 
carriers also exhibited a higher proliferation rate than wild-type individuals following 
stimulation of the B-cell receptor, CD40 and toll-like receptor 9 compared with wild-type B-
cells16. 
 
Rituximab, a monoclonal antibody against CD20 present on pre-B and mature B lymphocytes, 
was (fortuitously) the optimal therapeutic drug of choice in these patients because of the 
possible immunological defects in B cells caused by the mutation in PRKCD. Since one sibling 
developed anaphylaxis to rituximab, other B-cell targeted therapies such as ofatumumab (an 
alternative fully-humanised monoclonal antibody against CD20)17, or belimumab (a fully-
humanized monoclonal antibody against B-lymphocyte stimulator B-lyS)18 are being 
considered for future treatment19. Alternatively, it is possible that hematopoietic stem cell 
transplantation may ultimately be required, although to the best of our knowledge has not yet 
been performed in SLE caused by mutations in PRKCD (Belot A, personal communication).  
 
Interestingly the mother, who is a heterozygous carrier of the mutation, developed SLE during 
pregnancy with her third child. The combined contribution of heterozygous carriage and 
hormonal changes occurring during pregnancy may be responsible for the new-onset of SLE 
during pregnancy20. The youngest brother aged eighteen months at the time of writing also has 
the homozygous mutation and is thus far asymptomatic but will be closely monitored for the 
development of symptoms. 
 
CONCLUSIONS 
We have described a rare monogenic form of jSLE caused by a novel but very likely damaging 
homozygous mutation affecting the active region of PRKCD. Identification of this additional 
disease causing variant of PRKCD provides further supportive evidence for this gene to be 
included in routine genetic screening for suspected monogenic SLE. Securing this molecular 
diagnosis not only provided us with a definitive diagnosis, but also explained the dramatic and 
complete therapeutic response to B-cell depletion (despite failing other therapies), and will 
direct the choices made for future treatment options. Since the list of monogenic causes of SLE 
is increasing (Table 1), next-generation sequencing offers the opportunity to screen all the 
known genetic causes rapidly, and for a fraction of the cost of conventional sequencing, and 
should be considered in all cases of early-onset (<5-years) jSLE, particularly for 
consanguineous families.  
Table 1: Monogenic causes of systemic lupus erythematosus 
Gene Locus Inheritance Clinical features Onset of  
SLE/SLE-
like 
(years) 
SLE/ SLE-like features Specific  
treatment* 
References 
Complement Cascade     
 
1-40 
 
Fresh frozen plasma, 
HSCT 
6, 21-23 
      C1QA 1p.36.12 AR SLE, ICD, RI Mucocutaneous and renal  involvement, positive  
ANA, Anti-dsDNA, ENA antibodies, increased 
cardiovascular risk 
      C1QB 1p36.12 AR SLE, ICD, RI 
      C1QC 1p.36.11 AR SLE, ICD, RI 
      C1R 12p13 AR SLE, ICD, RI <1 Mucocutaneous ,neurological and renal involvement - 24 
      C1S 12p13 AR SLE, ICD, RI <1 Mucocutaneous and  renal involvement, autoimmune 
thyroiditis, autoimmune hepatitis 
- 25, 26 
      C2 6p21.3 AR SLE, RI, UCTD, vasculitis, Sjogren’s 
syndrome 
>10 Mucocutaneous, haematological and  renal 
involvement, arthritis 
- 1, 27-29 
      C4 6p21.3 AR SLE, ICD, RI, Rheumatoid arthritis 2-40 Mucocutaneous, haematological and  renal 
involvement, vasculitis 
- 30 
TREX1 3p21.31 AD 
 
 
AR 
SLE, FCL, RVCL 
 
 
AGS1 
4-adulthood 
 
 
<1 
Cold-induced chilblain lupus, photosensitive rash, 
haematological and neurological involvement, 
arthralgia/arthritis 
Cold-induced chilblain lupus 
- 
 
 
- 
31 
 
 
32, 33 
RNASAH2A 19p13 AR AGS4 <1 Cold-induced chilblain lupus - 32, 33 
RNASAH2B 13q14 AR AGS2 <1 Cold-induced chilblain lupus - 32, 33 
RNASAH2C 11q13 AR AGS3 <1 Cold-induced chilblain lupus - 32, 33 
SAMHD1 20q11 AR 
AD 
AGS5 
FCL 
<1 Cold-induced chilblain lupus 
Cold-induced chilblain lupus 
- 
- 
32, 33 
34 
ADAR 1q21.3 AR AGS6 <1 Cold-induced chilblain lupus - 35 
DNASE1 16p13.3 AD Sporadic SLE 9-13 Systemic lupus, Sjogren’s syndrome, high ANA - 5 
DNASE1L3 3p14.3 AR Familial SLE 2-12 Mucocutaneous and  renal involvement, positive 
ANCA and anti-cardiolipin antibodies 
- 36 
PRKCD 3p21.31 AR Familial SLE <5 Cutaneous vasculitis, haematological involvement, 
positive ANA and dsDNA antibodies 
- 16 
ACP5 19p13.2 AR SPENCD, skeletal dysplasia, delayed 
development, intracranial calcification, 
immune dysregulation 
<1-15 Haematological and  renal involvement, positive 
ANA 
- 37 
SLC7A7 14q11.2  Lysinuric protein intolerance with some cases 
of SLE 
>10 Renal involvement, vasculitis, haemophagocytic 
lymphohistiocytosis  
- 38, 39 
IFIH1 2q24.2 AD SLE with IgA deficiency, RI, limb spasticity  6-12 Arthritis, cutaneous vasculitis, haematological 
involvement, positive ANA and dsDNA antibodies, 
secondary antiphospholipid syndrome 
- 4 
TMEM173 5q31.2 AD Familial SLE 
 
2-20 Arthritis, cutaneous vasculitis, haematological and 
pulmonary involvement, positive ANA  
- 40 
 
AD: autosomal dominant, AGS: Aicardi-Goutières Syndrome, ANA: anti-nuclear antibody, ANCA: anti-neutrophil cytoplasmic antibody, AR: autosomal recessive, dsDNA: 
double stranded DND, ENA: extractable nuclear antigen, FCL: Familial Chilblain lupus, HSCT: haematopoietic stem cells transplantation, ICD: immune complex disease, 
RI: recurrent infection, RVCL: Retinal Vasculopathy with Cerebral Leukodystrophy, SLE: systemic lupus erythematosus, SPENCD: Spondyloenchondrodysplasia, UCTD: 
undifferentiated connective tissue disease 
*all reported treatments described are case reports
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  Figure 1 A: A 3-year-old with early-onset juvenile systemic lupus erythematosus caused by 
homozygous mutation of PRKCD manifesting with alopecia and rash affecting the scalp and 
face, with sparing of the nasolabial folds. Figure B: hepatosplenomegaly, and bruising from 
thrombocytopenia; Figure C & D: erythematous, non-pruritic, vasculitic rash affecting the 
palms and soles. 
 
 
Figure 2 A: Pedigree of the family. The index case is V-2; the affected sister is V-1. B: 
Sanger sequencing chromatogram of PRKCD at position c.1294 (in the red-dashed box). The 
reference base in wild type is G shown above the chromatogram. The chromatogram shows a 
heterozygous pattern with two peaks of T and G in parents, and a homozygous T in patient, 
affected sister and unaffected brother. (T is red and G is black). 
